×
About 8 results

France Uses Only Quarter of AstraZeneca Vaccine Doses: Ministry
https://www.medscape.com/viewarticle/946687

Mar 2nd, 2021 - PARIS (Reuters) - France has used only a quarter of its AstraZeneca COVID-19 vaccine doses, a health ministry official indicated on Tuesday, saying its utilisation rate stood at 24% as of Feb. 28, well below a target set at 80%-85%. This compares with 82% for vaccines made by Pfizer/BioNTech and 37% for those made by Moderna.

FDA Authorizes Emergency Use of Remdesivir for COVID-19
https://www.medscape.com/viewarticle/929836

Apr 30th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The US Food and Drug Administration (FDA) today issued an emergency use authorization (EUA) for remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. The investigational antiviral drug, manufactured by Gilead Sciences ...

De-escalation of Cancer Treatment: When Is Less Really More?
https://www.medscape.com/viewarticle/923402

Feb 4th, 2020 - This transcript has been edited for clarity. Kathy D. Miller, MD: Hi. I'm Dr Kathy Miller, professor and associate director of clinical research at the Indiana University Simon Cancer Center. Today I'm joined by Dr Eric Winer, chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute in Boston. Thank you for coming in, Eric. Eric P. Winer, MD: Thank you for having me. Miller:...

Neurologic AEs on Rise as Checkpoint Inhibitors Evolve
https://www.staging.medscape.com/viewarticle/885495

Sep 10th, 2017 - Fewer than 3% of cancer patients developed neurologic adverse events (AEs) after treatment with two of the newer immune checkpoint inhibitors, results from a single-center, retrospective cohort study show. Although this rate may seem low, clinicians can expect to see more serious neurologic complications more often, as treatment with anti–programmed death-1 (anti-PD-1) monoclonal antibodies is ...

Neurologic AEs on Rise as Checkpoint Inhibitors Evolve
https://www.medscape.com/viewarticle/885495

Sep 10th, 2017 - Fewer than 3% of cancer patients developed neurologic adverse events (AEs) after treatment with two of the newer immune checkpoint inhibitors, results from a single-center, retrospective cohort study show. Although this rate may seem low, clinicians can expect to see more serious neurologic complications more often, as treatment with anti–programmed death-1 (anti-PD-1) monoclonal antibodies is ...

Neurologic AEs on Rise as Checkpoint Inhibitors Evolve
https://emedicine.medscape.com/viewarticle/885495

The CME Situation Room: How Will Biosimilars Impact Oncology Care?
https://www.medscape.com/viewarticle/901234

De-escalation of Cancer Treatment: When Is Less Really More?
https://emedicine.medscape.com/viewarticle/923402

This transcript has been edited for clarity. Kathy D. Miller, MD: Hi. I'm Dr Kathy Miller, professor and associate director of clinical research at the Indiana University Simon Cancer Center. Today I'm joined by Dr Eric Winer, chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute in Boston. Thank you for coming in, Eric. Eric P. Winer, MD: Thank you for having me. Miller:...